Log In Sign up
The largest database of trusted experimental protocols

Anti cd138 pe cy7 clone 281 2

Manufactured by BioLegend
Visit Supplier
Sourced in United States

Anti-CD138-PE-Cy7 (clone 281-2) is a fluorochrome-conjugated monoclonal antibody that binds to the CD138 protein. CD138, also known as Syndecan-1, is a cell surface proteoglycan expressed on plasma cells. This antibody can be used to identify and analyze plasma cells in flow cytometry applications.

Automatically generated - may contain errors

Lab products found in correlation

Anti ly6c pe, by BioLegend (3 mentions) Anti tcrβ pe cy7, by BioLegend (2 mentions) Anti nk1.1 apc clone pk 136, by BioLegend (2 mentions) Anti cd1d pe clone, by BioLegend (2 mentions) Anti b220 fitc clone ra3 6b2, by BioLegend (2 mentions) Anti gl7 pe clone gl7, by BioLegend (2 mentions) Anti cd4 fitc clone, by BioLegend (2 mentions) Anti cd8 pe clone, by BioLegend (2 mentions)

Close spelling variants of this product

CD138-PE (14 citations) Anti-CD138 (14 citations) Anti-CD138-PE (6 citations) CD138 (281-2; (5 citations) CD138-PE/Cy7 (5 citations) Anti-CD138 (281-2, (4 citations) Anti-CD138 (clone 281-2, (2 citations) CD138-PE (281–2, (2 citations)

3 protocols using anti cd138 pe cy7 clone 281 2

1

Multiparameter Flow Cytometry Panels

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following antibodies (BioLegend, San Diego, CA, USA) were added to 100 µL aliquots of 105 Fc-blocked splenocytes prepared as described above to make a final 1/600 dilution: anti-CD1d-PE(clone 1B1), anti-B220-FITC (clone RA3-6B2), anti-CD93-APC (clone AA4.1), anti-CD138-PE-Cy7 (clone 281-2), anti-GL7-PE (clone GL7), anti-Ly6G-Alexa488 (clone 1A8), anti-Ly6C-PE (clone HK 1.4), anti-CD4-FITC (clone GK 1.5), anti-CD8-PE (clone 53-6.7), anti-NK1.1-APC(clone PK 136), anti-TCRβ-PE-Cy7 (clone H57-597).
Radwanska M., Nguyen H.T, & Magez S. (2021). African Trypanosomosis Obliterates DTPa Vaccine-Induced Functional Memory So That Post-Treatment Bordetella pertussis Challenge Fails to Trigger a Protective Recall Response. Vaccines, 9(6), 603.
+ Open protocol
+ Expand
2

Multiparameter Flow Cytometry Panels

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following antibodies (BioLegend, San Diego, CA, USA) were added to 100 µL aliquots of 105 Fc-blocked splenocytes prepared as described above to make a final 1/600 dilution: anti-CD1d-PE(clone 1B1), anti-B220-FITC (clone RA3-6B2), anti-CD93-APC (clone AA4.1), anti-CD138-PE-Cy7 (clone 281-2), anti-GL7-PE (clone GL7), anti-Ly6G-Alexa488 (clone 1A8), anti-Ly6C-PE (clone HK 1.4), anti-CD4-FITC (clone GK 1.5), anti-CD8-PE (clone 53-6.7), anti-NK1.1-APC(clone PK 136), anti-TCRβ-PE-Cy7 (clone H57-597).
Magez S., Li Z., Nguyen H.T., Pinto Torres J.E., Van Wielendaele P., Radwanska M., Began J., Zoll S, & Sterckx Y.G. (2021). The History of Anti-Trypanosome Vaccine Development Shows That Highly Immunogenic and Exposed Pathogen-Derived Antigens Are Not Necessarily Good Target Candidates: Enolase and ISG75 as Examples. Pathogens, 10(8), 1050.
+ Open protocol
+ Expand
3

Comprehensive Immunophenotyping of Murine Splenocytes

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following antibodies (Biolegend, CA, USA) were added to 100 μl aliquots of 105 Fc-blocked splenocytes prepared as described above to make final 1/600 dilution: anti-CD1d-PE(clone 1B1), anti-CD23-APC (clone B3B4), anti-B220-FITC and anti-B220-PE-Cy7 (clone RA3-6B2), anti-CD93-APC and anti-CD93-PE-Cy7 (clone AA4.1), anti-CD138-PE-Cy7 (clone 281–2), anti-GL7-PE (clone GL7), anti-IgD-APC (clone 11-26c.2a), anti-Ter119-PE (clone TER-119), anti-Ly6G-Alexa488 (clone 1A8), anti-Ly6C-PE (clone HK 1.4). Anti-IgM-PE (clone X-54) was purchased from Miltenyi Biotec (Bergisch Gladbach, Germany) and diluted 1/11 in 100 μl aliquots of 105 Fc-blocked splenocytes.
Nguyen H.T., Guevarra R.B., Magez S, & Radwanska M. (2021). Single-cell transcriptome profiling and the use of AID deficient mice reveal that B cell activation combined with antibody class switch recombination and somatic hypermutation do not benefit the control of experimental trypanosomosis. PLoS Pathogens, 17(11), e1010026.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!